Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12854188 | 0.78 | — | — | |
| SCHEMBL6736576 | 0.73 | — | — | |
| SCHEMBL19041027 | 0.70 | — | — | |
| SCHEMBL20029368 | 0.70 | — | — | |
| SCHEMBL7995525 | 0.70 | — | — | |
| SCHEMBL23221279 | 0.70 | IDO1 (0.32) | PGRCYP2C19 | |
| SCHEMBL22698692 | 0.70 | IDO1 (0.32) | PGRCYP2C19 | |
| SCHEMBL20715644 | 0.70 | — | — | |
| SCHEMBL14084264 | 0.70 | — | — | |
| SCHEMBL20204351 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, BCR | TAAR1 3788/4885UBE2N 3330/4885AAK1 4200/4885 |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | TAAR1 3788/4885UBE2N 3330/4885AAK1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.